Executive Vice President and Chief Commercial Officer Andrew Callos executed a stock sale in Cytokinetics Inc. (NASDAQ:CYTK) on April 15, 2026. Callos sold 7,449 shares of common stock at $66.02 per share, producing a total transaction value of $491,782.
The disposition came while the shares traded close to their 52-week peak of $70.98 and after a notable 72% gain in the past year. Following the sale, Callos retains direct ownership of 58,555 Cytokinetics shares. The transaction was recorded in a Form 4 filing with the U.S. Securities and Exchange Commission.
Analyst coverage and valuation commentary for Cytokinetics has been active in recent weeks. Several broker research notes and target-price adjustments accompany the company’s ongoing clinical and commercial developments tied to Myqorzo (aficamten) and the coming Phase 3 ACACIA trial in non-obstructive hypertrophic cardiomyopathy.
- Evercore ISI reiterated an Outperform rating and set a price target of $80, citing the potential implications of the ACACIA trial.
- Mizuho raised its price target to $100, extended the intellectual property projection for aficamten to 2041, and increased its probability of success for the condition to 75%.
- JPMorgan adjusted its price target to $75 while maintaining an Overweight rating, pointing to a favorable market response to the recent approval of Myqorzo for obstructive hypertrophic cardiomyopathy.
- Stifel kept a Buy rating with a $98 price target and assigned a 70% probability of success to the ACACIA trial based on prior data.
- Leerink Partners reiterated an Outperform rating and a price target of $84, expressing confidence in the early U.S. launch of Myqorzo and anticipation around upcoming trial results.
One valuation note included in recent commentary indicates the shares are trading below their assessed Fair Value, according to a proprietary analysis cited in market commentary. For investors seeking more comprehensive valuation and research coverage, expanded reports covering this and other U.S. equities are available from subscription research services.
This report summarizes the insider transaction, current analyst positioning, and valuation context as disclosed in company filings and published analyst notes. It does not add or infer outcomes beyond the information contained in those documents.